Dr. Orlowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2406 Century Pl Se
Hickory, NC 28602Phone+1 828-324-9550Fax+1 828-324-4154
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1981 - 1983
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1978 - 1981- Washington University in St. Louis School of MedicineClass of 1978
Certifications & Licensure
NC State Medical License 1982 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 38 citationsBone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK StudyNoopur Raje, Robert Vescio, Charles W. Montgomery, Ashraf Badros, Nikhil C. Munshi
Clinical Cancer Research. 2016-03-15
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
